The Impact of microRNAs in Breast Cancer Angiogenesis and Progression

Author(s): Kontomanolis N. Emmanuel, Fasoulakis Zacharias*, Papamanolis Valentinos, Koliantzaki Sofia, Dimopoulos Georgios, Kambas J. Nikolaos.

Journal Name: MicroRNA

Volume 8 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Objective: The study aims to review the recent data considering the expression profile and the role of microRNAs in breast tumorigenesis, and their impact on -the vital for breast cancer progression- angiogenesis.

Methods: PubMed was searched for studies focused on data that associate microRNA with breast cancer, using the terms ''breast”, “mammary gland”, “neoplasia'', “angiogenesis” and ''microRNA'' between 1997-2018.

Results: Aberrant expression of several circulating and tissue miRNAs is observed in human breast neoplasms with the deregulation of several miRNAs having a major participation in breast cancer progression. Angiogenesis seems to be directly affected by either overexpression or down regulation of many miRNAs, defining the overall prognostic rates. Many miRNAs differentially expressed in breast cancer that reveal a key role in suppression - progression and metastasis of breast cancer along with the contribution of the EGF, TNF-a and EGF cytokines.

Conclusion Angiogenesis has proven to be vital for tumor development and metastasis while microRNAs are proposed to have multiple biological roles, including participation in immunosuppressive, immunomodulatory and recent studies reveal their implication in angiogenesis and its possible use as prognostic factors in cancer Even though larger studies are needed in order to reach safe conclusions, important steps are made that reveal the connection of serum microRNA expression to the angiogenic course of breast cancer, while miRNAs could be potential prognostic factors for the different breast cancer types.

Keywords: Breast, cancer, microRNA, neoplasia, protein, vessel.

[1]
Kontomanolis EN, Kalagasidou SFZ. MicroRNAs as potential serum biomarkers for early detection of ectopic pregnancy. Cureus 2018; 10: e2344.
[2]
Miyake M, Goodison S, Lawton A, et al. Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway. Oncogene 2015; 34: 890-901.
[3]
Bartel DP, Lee R, Feinbaum R. MicroRNAs : genomics, biogenesis, mechanism, and function genomics. Cell 2004; 116: 281-97.
[4]
Winter J, Jung S, Keller S, et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11: 228-34.
[5]
MacFarlane L-A, Murphy P. MicroRNA: biogenesis, function and role in cancer. Curr Genomics 2010; 11: 537-61.
[6]
Longatto FA, Lopes JM, Schmitt FC. Angiogenesis and breast cancer. J Oncol 2010; 2010: 1782-90.
[7]
Folkman J, Judah F. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
[8]
Kontomanolis NE, Pouliliou S, Kalagasidou S, et al. The notch pathway in breast cancer progression. Sci World J 2018.
[http://dx.doi.org/10.1155/2018/2415489]
[9]
Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol 2015; 1: 505-27.
[10]
Zou Q, Tang Q, Pan Y, et al. MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1. Exp Ther Med 2017; 14: 1009-16.
[11]
Zou Q, Yi W, Huang J, et al. MicroRNA-375 targets PAX6 and inhibits the viability, migration and invasion of human breast cancer MCF-7 cells. Exp Ther Med 2017; 14: 1198-204.
[12]
Li W, Li G, Fan Z, et al. Tumor-suppressive microRNA-452 inhibits migration and invasion of breast cancer cells by directly targeting RAB11A. Oncol Lett 2017; 14: 2559-65.
[13]
Zehentmayr F, Hauser-Kronberger C, Zellinger B, et al. HSA-miR-375 is a predictor of local control in early stage breast cancer. Clin Epigenetics 2016; 8: 28.
[14]
Sheng J, Xu Z. Three decades of research on angiogenin: a review and perspective. Acta Biochim Biophys Sin Sinica 2016; 48: 399-410.
[15]
He T, Qi F, Jia L, et al. Tumor cell-secreted angiogenin induces angiogenic activity of endothelial cells by suppressing miR-542-3p. Cancer Lett 2015; 368: 115-25.
[16]
Rykala J, Przybylowska K, Majsterek I, et al. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathol Oncol Res 2011; 17: 809-17.
[17]
Roth C, Rack B, Müller V, et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010; 12: R90.
[18]
Schneble E, Jinga D-C, Peoples G. Breast cancer immunotherapy. Maedica (Buchar) 2015; 10: 185-91.
[19]
Page DB, Naidoo J, McArthur HL. Emerging immunotherapy strategies in breast cancer. Immunotherapy 2014; 6: 195-209.
[20]
Roth C, Rack B, Muller V, et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010; 12: R90.
[21]
Si H, Sun X, Chen Y, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol 2013; 139: 223-9.
[22]
Smith L, Baxter EW, Chambers PA, et al. Down-regulation of miR-92 in breast epithelial cells and in normal but not tumour fibroblasts contributes to breast carcinogenesis. PLoS One 2015; 10(10): e0139698.
[23]
McArthur HL, Page DB. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. Clin Adv Hematol Oncol 2016; 14: 922-33.
[24]
Bachelder RRE, Crago A, Chung J, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001; 61: 5736-40.
[25]
Yan L-X, Huang X-F, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14: 2348-60.
[26]
Wu H, Zhu S, Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 2009; 19: 439-48.
[27]
Zhu S, Si ML, Wu H, et al. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007; 282: 14328-36.
[28]
Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010; 251: 499-505.
[29]
Tsai H-P, Huang S-F, Li C-F, et al. Differential microRNA expression in breast cancer with different onset age. PLoS One 2018; 13: e0191195.
[30]
Mar-Aguilar F, Luna-Aguirre CM, Moreno-Rocha JC, et al. Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue. Asia Pac J Clin Oncol 2013; 9: 53-9.
[31]
Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers 2013; 34: 163-9.
[32]
Zhang J, Yang J, Zhang X, et al. MicroRNA-10b expression in breast cancer and its clinical association. PLoS One 13(2): e0192509.
[33]
Wu Q, Wang C, Lu Z, et al. Analysis of serum genome-wide microRNAs for breast cancer detection. Clin Chim Acta 2012; 413: 1058-65.
[34]
Zhou J, Tian Y, Li J, et al. MiR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun 2013; 433: 207-12.
[35]
Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-61.
[36]
Wang S, Bian C, Yang Z, et al. miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 2009; 34: 1461-6.
[37]
Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-8.
[38]
Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008; 10: 202-10.
[39]
Edmonds MD, Hurst DR, Vaidya KS, et al. Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer 2009; 125: 1778-85.
[40]
Dykxhoorn DM, Wu Y, Xie H, et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 2009; 4(9): e7181.
[41]
Campo L, Turley H, Han C, et al. Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. J Pathol 2005; 205: 585-91.
[42]
Chopra V, Dinh TV, Hannigan EV. Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J Cancer Res Clin Oncol 1997; 123: 167-72.
[43]
Montero S, Guzmán C, Cortés-Funes H, et al. Angiogenin expression and prognosis in primary breast carcinoma. Clin Cancer Res 1998; 4: 2161-8.
[44]
He T, Qi F, Jia L, et al. MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2. J Pathol 2014; 232: 499-508.
[45]
Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15: 272-84.
[46]
Kuhnert F, Mancuso MR, Hampton J, et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development 2008; 135: 3989-93.
[47]
Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 2008; 111: 1217-26.
[48]
Otsuka M, Zheng M, Hayashi M, et al. Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice. J Clin Invest 2008; 118: 1944-54.
[49]
Hua Z, Lv Q, Ye W, et al. MiRNA-directed regulation of VEGF and other angiogenic under hypoxia. PLoS One 2006; 1(1): e116.
[50]
Wang CD, Long K, Jin L, et al. Identification of conserved microRNAs in peripheral blood from giant panda: Expression of mammary gland-related microRNAs during late pregnancy and early lactation. Genet Mol Res 2015; 14: 14216-28.
[51]
Poliseno L, Tuccoli A, Mariani L, et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006; 108: 3068-71.
[52]
Kuehbacher A, Urbich C, Zeiher AM, et al. Role of dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007; 101: 59-68.
[53]
Wu X, Somlo G, Yu Y, et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med 2012; 10: 42.
[54]
Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603.
[55]
Iorio MV, Ferracin M, Liu C, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-70.
[56]
Eastlack S, Alahari S. MicroRNA and breast cancer: understanding pathogenesis, improving management. Noncoding RNA 2015; 1: 17-43.
[57]
Chakrabarti M, Khandkar M, Banik NL, et al. Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells. Brain Res 2012; 1454: 1-13.
[58]
Tashkandi H, Shah N, Patel Y, et al. Identification of new miRNA biomarkers associated with HER2-positive breast cancers. Oncoscience 2015; 2: 924-9.
[59]
Lee JA, Lee HY, Lee ES, et al. Prognostic implications of microRNA-21 overexpression in invasive ductal carcinomas of the breast. J Breast Cancer 2011; 14: 269-75.
[60]
Persson H, Kvist A, Rego N, et al. Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res 2011; 71: 78-86.
[61]
Wee EJH, Peters K, Nair SS, et al. Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-miR-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer. Oncogene 2012; 31: 4182-95.
[62]
Lowery AJ, Miller N, Devaney A, et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009; 11: R27.
[63]
Kurozumi S, Yamaguchi Y, Kurosumi M, et al. Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J Hum Genet 2017; 62: 15-24.
[64]
Lyng MB, Lænkholm AV, Søkilde R, et al. Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant Tamoxifen mono-therapy: a DBCG study. PLoS One 2012; 7(5): e36170.
[65]
Ward A, Shukla K, Balwierz A, et al. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol 2014; 233: 368-79.
[66]
Bacci M, Giannoni E, Fearns A, et al. miR-155 drives metabolic reprogramming of ER+ breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors. Cancer Res 2016; 76: 1615-26.
[67]
Yu X, Li R, Shi W, et al. Silencing of microRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Biomed Pharmacother 2016; 77: 37-44.
[68]
Mertens-Talcott SU, Noratto GD, Li X, et al. Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: role of Sp transcription factors and microRNA-27a:ZBTB10. Mol Carcinog 2013; 52: 591-602.
[69]
Cheng C, Fu X, Alves P, et al. MRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol 2009; 10(9): R90.
[70]
Zhu W, Qin W, Atasoy U, et al. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2009; 2: 89.
[71]
Vazquez-martin A, Colomer R, Menendez JA. Protein array technology to detect HER2 (erbB-2)-induced ‘cytokine signature’ in breast cancer. Eur J Cancer 2007; 43: 1117-24.
[72]
Mojtahedi Z, Safaei A, Yousefi Z, et al. Immunoproteomics of HER2-positive and HER2-negative breast cancer patients with positive lymph nodes. OMICS 2011; 15: 409-18.
[73]
Papa A, Caruso D, Tomao S, et al. Triple-negative breast cancer: investigating potential molecular therapeutic target. Expert Opin Ther Targets 2015; 19: 55-75.
[74]
Radojicic J, Zaravinos A, Vrekoussis T, et al. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011; 10: 507-17.
[75]
Lü L, Mao X, Shi P, et al. MicroRNAs in the prognosis of triple-negative breast cancer. Medicine (Baltimore) 2017; 96(22): e7085.
[76]
Turashvili G, Lightbody ED, Tyryshkin K, et al. Novel prognostic and predictive microRNA targets for triple-negative breast cancer. FASEB J 2018; fj201800120R
[http://dx.doi.org/10.1096/fj.201800120R]
[77]
Yao L, Liu Y, Cao Z, et al. MicroRNA-493 is a prognostic factor in triple-negative breast cancer. Cancer Sci 2018; 109(7): 2294-301.
[78]
YI B. Ma R, Xi Y. Abstract 5180: MicroRNA and triple negative breast cancer. Cancer Res 2018; 78: 5180.
[79]
Roberti MP, Arriaga JM, Bianchini M, et al. Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther 2012; 13: 1123-40.
[80]
Borin TF, Zuccari DAPC. Jardim-Perassi B V, et al HET0016, a selective inhibitor of 20-HETE synthesis, decreases pro-angiogenic factors and inhibits growth of triple negative breast cancer in mice. PLoS One 2014; 9(12): e116247.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 8
ISSUE: 2
Year: 2019
Page: [101 - 109]
Pages: 9
DOI: 10.2174/2211536607666181017122921

Article Metrics

PDF: 44
HTML: 4
PRC: 1